Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder

Core Insights - Neurocrine Biosciences, Inc. announced new data from the Phase 2 SAVITRI study demonstrating significant improvement in depression severity at Day 28 and Day 56 with the administration of 1 mg osavampator (NBI-1065845) [1] Group 1 - The Phase 2 SAVITRI study showed statistically significant improvement in depression severity [1] - The improvement was clinically meaningful at both Day 28 and Day 56 [1] - The treatment involved once-daily oral administration of 1 mg osavampator [1]